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Abstract
Objective
An intronic GGGGCC-repeat expansion of C9ORF72 is the most common genetic variant of
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The mechanism of neuro-
degeneration is unknown, but a direct effect on RNA processing mediated by RNA foci tran-
scribed from the repeat sequence has been proposed.
Methods
Gene expression profiling utilised total RNA extracted from motor neurons and lymphoblas-
toid cell lines derived from human ALS patients, including those with an expansion of
C9ORF72, and controls. In lymphoblastoid cell lines, expansion length and the frequency of
sense and antisense RNA foci was also examined.
Results
Gene level analysis revealed a number of differentially expressed networks and both cell
types exhibited dysregulation of a network functionally enriched for genes encoding ‘RNA
splicing’ proteins. There was a significant overlap of these genes with an independently
generated list of GGGGCC-repeat protein binding partners. At the exon level, in lympho-
blastoid cells derived from C9ORF72-ALS patients splicing consistency was lower than in
lines derived from non-C9ORF72 ALS patients or controls; furthermore splicing consistency
was lower in samples derived from patients with faster disease progression. Frequency of
sense RNA foci showed a trend towards being higher in lymphoblastoid cells derived from
patients with shorter survival, but there was no detectable correlation between disease se-
verity and DNA expansion length.
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Significance
Up-regulation of genes encoding predicted binding partners of the C9ORF72 expansion is
consistent with an attempted compensation for sequestration of these proteins. A number
of studies have analysed changes in the transcriptome caused by C9ORF72 expansion, but
to date findings have been inconsistent. As a potential explanation we suggest that dynamic
sequestration of RNA processing proteins by RNA foci might lead to a loss of splicing con-
sistency; indeed in our samples measurement of splicing consistency correlates with dis-
ease severity.
Introduction
GGGGCC repeat expansions within intron 1 of the C9ORF72 gene are the most common
cause of familial amyotrophic lateral sclerosis (ALS) and familial frontotemporal degeneration
(FTD) [1,2], though how this genetic change results in neuronal injury is not yet understood.
Evidence is being gathered for a gain-of-function toxicity mediated by either sequestration of
RNA binding proteins (RBPs) by RNA foci transcribed from the repeat sequence [3–8], or via
repeat associated non-ATG (RAN) translation of the repeat sequence to produce a dipeptide
repeat protein [9–11], or a combination of both mechanisms.
Gene expression profiling has the potential to identify biological pathways aberrantly affect-
ed by the C9ORF72 expansion. In addition, if toxicity is mediated by nuclear RNA foci devel-
oped from an intronic expansion, then transcriptome changes may be relatively upstream in
disease pathogenesis [12]. On this basis we have studied gene expression changes in motor neu-
rons and lymphoblastoid cell lines derived from individuals with C9ORF72-ALS.
We have previously suggested that dynamic sequestration by RNA foci of a number of RBPs
might affect nuclear speckle function and thus disrupt mRNA splicing [8]. It has been proposed
that splicing errors are a normal occurrence for which the cell is able to compensate [13]. There-
fore an excessive splicing error rate may not immediately result in disease; however in time com-
pensatory mechanisms might be overwhelmed in vulnerable cells. This is more consistent with
the variable phenotype and late age of onset seen in C9ORF72-ALS than a model of binary toxic-
ity resulting from a small number of specific splicing errors. Therefore we aimed to derive a mea-
sure of the overall splicing error rate in biosamples containing the C9ORF72 repeat expansion.
Additionally we used Southern hybridisation and RNA fluorescence in-situ hybridisation
(FISH) to examine the relationship between the changes in the splicing error rate, disease severi-
ty, the length of the GGGGCC repeat expansion and the abundance of RNA foci.
Results
Transcriptome analysis
Motor neurons. Network analysis using WGCNA identified six significant networks with-
in 5,000 genes considered (Fig 1) all of which were differentially expressed between C9ORF72-
ALS and control groups, and showed significant functional enrichment (Table 1). Based on the
median fold change, three networks were down-regulated and three networks were up-regulat-
ed in C9ORF72-ALS (Table 1). Specifically, within the brown network which was significantly
enriched for transcripts related to the Gene Ontology (GO) term ‘RNA splicing’, 58.2% of tran-
scripts were up-regulated. The yellow and green networks were also up-regulated and function-
ally enriched for ‘male sex differentiation’ and ‘erythrocyte homeostasis’ respectively. The
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turquoise, blue and red networks were all down-regulated and functionally enriched for ‘cho-
lesterol biosynthetic process’, ‘regulation of glucose metabolic process’ and ‘regulation of nucle-
ar division’ respectively.
Lymphoblastoid cell lines. Two samples failed the Affymetrix quality control (QC) assess-
ment and were excluded from the analysis based upon a low % presence call and/or AUC
value. Network analysis using WGCNA identified nine significant networks which were differ-
entially expressed between C9ORF72-ALS and control groups (Fig 2), and showed significant
functional enrichment (Table 2). Based on the median fold change, five networks were down-
Fig 1. Gene level network analysis of transcriptome changes in motor neurons fromC9ORF72-ALS
cases.WGCNA analysis identified six gene networks which were dysregulated between C9ORF72-ALS and
control samples. A clustering tree and heat map are shown illustrating separation of the gene networks, a
lower branch height or darker colour denotes a greater Pearson correlation coefficient between pairs
of genes.
doi:10.1371/journal.pone.0127376.g001
Table 1. Gene level network analysis of transcriptome changes in motor neurons fromC9ORF72-ALS cases.
Network Number of
Genes
P-value C9ORF72-ALS Vs
Control
Top Gene Ontology Enrichment P-value for Enrichment
Analysis
Median Fold
Change
Turquoise 1555 0.008 Cholesterol biosynthetic process 0.001 0.62
Blue 1020 0.003 Regulation of glucose metabolic
process
0.01 0.47
Brown 901 0.008 RNA splicing 7.45E-04 1.49
Yellow 635 0.003 Male sex differentiation 0.02 1.91
Green 579 0.0005 Erythrocyte homeostasis 0.01 1.75
Red 321 0.006 Regulation of nuclear division 0.01 0.49
WGCNA analysis identiﬁed six gene networks which were dysregulated between C9ORF72-ALS and control samples. The median fold change of genes
within each network and the functional enrichment of each of the gene networks is tabulated. A fold change of >1 equates to up-regulation and a fold
change of <1 equates to down-regulation.
doi:10.1371/journal.pone.0127376.t001
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Fig 2. Gene level network analysis of transcriptome changes in lymphoblastoid cell lines derived
fromC9ORF72-ALS cases.WGCNA analysis identified nine gene networks which were dysregulated
betweenC9ORF72-ALS and control samples. A clustering tree and heat map are shown illustrating
separation of the gene networks, a lower branch height or darker colour denotes a greater Pearson
correlation coefficient between pairs of genes. The median fold change of genes within each network and the
functional enrichment of each of the gene networks is tabulated (B). A fold change of >1 equates to up-
regulation and a fold change of <1 equates to down-regulation.
doi:10.1371/journal.pone.0127376.g002
Table 2. Gene level network analysis of transcriptome changes in lymphoblastoid cell lines derived from C9ORF72-ALS cases.
Network Number of
Genes
P-value C9ORF72-ALS Vs
Control
Top Gene Ontology
Enrichment
P-value for Enrichment
Analysis
Median Fold
Change
Turquoise 4653 8.11E-64 Positive regulation of apoptosis 0.01 1.19
Blue 1403 0.0000001 Regulation of action potential in
neuron
0.02 0.88
Brown 1038 4.69E-09 Protein catabolic process 0.002 0.79
Yellow 854 2.48E-09 Synaptic transmission 0.004 1.16
Green 537 0.0000002 RNA splicing 1.50E-05 1.27
Red 427 9.17E-08 Positive regulation of apoptosis 0.02 0.74
Black 391 3.43E-09 Striated muscle tissue
development
0.02 0.86
Pink 367 3.54E-08 Inﬂammatory response 0.004 0.86
Magenta 336 0.0000001 Protein catabolic process 1.43E-05 1.53
WGCNA analysis identiﬁed nine gene networks which were dysregulated between C9ORF72-ALS and control samples. The median fold change of genes
within each network and the functional enrichment of each of the gene networks is tabulated. A fold change of >1 equates to up-regulation and a fold
change of <1 equates to down-regulation.
doi:10.1371/journal.pone.0127376.t002
Splicing Dysregulation in C9ORF72-ALS
PLOSONE | DOI:10.1371/journal.pone.0127376 May 27, 2015 4 / 17
regulated and four networks were up-regulated in C9ORF72-ALS (Table 2). Specifically 92% of
transcripts were up-regulated within the green network, which was significantly enriched for
transcripts related to the GO term ‘RNA splicing’. The turquoise and red networks were both
functionally enriched for genes related to ‘positive regulation of apoptosis’, the blue and yellow
networks were functionally enriched for categories directly related to neuronal function, and
the black network was functionally enriched for ‘striated muscle tissue development’; the pink
network was functionally enriched for ‘inflammatory response’; and the brown and magenta
networks were functionally enriched for ‘protein catabolic process.’
Analysis of networks enriched for the GO term ‘RNA Splicing’. The brown network in
the motor neurons and the green network in the lymphoblastoid cell lines were both up-regu-
lated in C9ORF72-ALS samples and significantly enriched for transcripts related to the GO
term ‘RNA splicing.’ We set out to determine whether the two networks contained similar tran-
scripts or only transcripts with similar functional enrichment.
To make this comparison we reverted to the original lists of transcripts not filtered by Pear-
son correlation coefficient because computational burden was no longer an issue, and we were
interested in all transcripts associated with the network signal and not just the most correlated.
Examination of all genes significantly correlated (as quantified by Pearson correlation coeffi-
cient) (p<0.05) with the brown network signal and associated with the GO term ‘RNA Process-
ing’ in motor neurons derived from C9ORF72-ALS patients revealed 88 transcripts encoding
74 unique genes (S1 Table). Examination of all genes significantly correlated (p<0.05) with the
green network signal and associated with the GO term ‘RNA Processing’ in lymphoblastoid
cells derived from C9ORF72-ALS patients revealed 459 transcripts encoding 236 unique genes
(S1 Table). Given the difference in cell types and microarray platforms, there was evidence for
significant similarity between the lists: 54% of the motor neuron list was also present within
the lymphoblastoid cell list. Previously we have identified candidate binding partners of the
GGGGCC repeat expansion by RNA pulldown and mass spectroscopy [8]. 20% of the unique
hits identified in this way were present within the lymphoblastoid cell line list (p<0.0001) of
which 89% were up-regulated in the C9ORF72-ALS samples compared to controls (S1 Table);
and 10% of the unique hits were present within the motor neuron list (p<0.0001) of which
77% were up-regulated in the C9ORF72-ALS samples compared to controls (S1 Table).
Analysis of splicing. There was no significant difference in the total number of splicing
events observed in lymphoblastoid cell lines derived from C9ORF72-ALS patients, non-
C9ORF72-ALS patients and controls (Fig 3). However, the nature of those splicing events was
significantly different. It is expected that functionally appropriate splicing would be similar in
samples of a particular group and therefore we propose that splicing consistency is a marker
of the error rate in RNA splicing. Splicing consistency was significantly reduced in the
C9ORF72-ALS group compared to non-C9ORF72-ALS patients and controls (Fig 4A, S1 Fig).
It is noteworthy that control cases do not share a common disease process and therefore might
be expected to have quite different patterns of splicing. This is good evidence that splicing in
C9ORF72-ALS is actively disrupted. In addition, splicing was less consistent in C9ORF72-ALS
patients who lived<2 years following diagnosis compared to those that lived>4 years suggest-
ing a link with the aggressiveness of the disease course (Fig 4B).
qPCR based validation of transcriptome changes
Candidates for qPCR validation were chosen from those genes which were up-regulated in the
lymphoblastoid cells derived from C9ORF72-ALS cases compared to controls, and also identified
as candidate binding partners of the GGGGCC repeat expansion by RNA pulldown and mass
Splicing Dysregulation in C9ORF72-ALS
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spectroscopy [8]. qPCR confirmed up-regulation ofHNRNPF (1.43 fold, t-test, p = 0.001), RBM3
(1.18 fold, t-test, p = 0.03) and FUS (1.35 fold, t-test, p = 0.005) but notHNRNPH2.
Estimation of expansion size and quantification of the abundance of
RNA foci in lymphoblastoid cell lines
GGGGCC repeat expansion size and abundance of sense and antisense RNA foci was deter-
mined in lymphoblastoid cell lines derived from 17 patients with short (<2 years) disease dura-
tion and 7 patients with long (>4 years) disease duration. No difference in minimum (t-test,
p = 0.10), modal (t-test, p = 0.41) or maximum (t-test, p = 0.57) repeat size was detectable be-
tween groups by Southern blotting (data not shown).
The frequency of lymphoblastoid cells containing sense RNA foci was higher in lines de-
rived from 3 patients with short (<2 years) disease duration compared to lines derived from 3
patients with long (>4 years) disease duration, however this trend did not reach significance
(average frequency of sense foci+ cells was 0.35 versus 0.12, t-test, p = 0.099). There was no
such trend in the frequency of lymphoblastoid cells containing antisense RNA foci (average
frequency of antisense foci+ cells 0.20 versus 0.32, t-test, p = 0.29). Example cells are shown in
Fig 5.
Fig 3. Frequency of exon inclusion and exclusion events. Plots of median and 95%CI for numbers of (A)
exon inclusion and (B) exon exclusion events inC9ORF72-ALS (+), non-C9ORF72 ALS (-) and control (C)
derived lymphoblastoid cell lines, as determined by FIRMA score. There was no significant difference
between sample groups.
doi:10.1371/journal.pone.0127376.g003
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Discussion
There is an urgent need to understand the mechanisms of neuronal injury in C9ORF72-disease.
In order to establish the biological pathways altered by the presence of the GGGGCC repeat ex-
pansion we carried out gene expression profiling of isolated motor neurons from spinal cord
and lymphoblastoid cell lines derived from human ALS patients and controls. Moreover, it has
been suggested that the C9ORF72 expansion has a direct effect on the transcriptome, possibly
via the formation of RNA foci [1,8]; if this is the case then transcriptome changes may repre-
sent a relatively upstream component of pathogenesis and a suitable therapeutic target.
Transcriptome analysis in C9ORF72-ALS motor neurons
Six gene networks were identified as differentially expressed between C9ORF72-ALS and con-
trol motor neurons (Fig 1, Table 1). Several networks were significantly enriched for GO cate-
gories previously implicated in ALS including ‘cholesterol biosynthetic process’ which occurs
primarily in the endoplasmic reticulum (ER) [14], ‘regulation of glucose metabolic process’
[15], ‘regulation of nuclear division’ [16] and ‘RNA splicing’ [17] (Table 1). The ‘RNA splicing’
network overlapped with a similar network in the lymphoblastoid cells and will be discussed
further below.
Fig 4. Plots of θ against the mean splicing rate with 95% confidence intervals. Exon inclusion events are shown in the left panel and exclusion inclusion
events are shown in the right panel. θ is higher indicating reduced consistency of splicing in (A)C9ORF72-ALS (+) compared to non-C9ORF72 ALS (-) and
control (C) derived lymphoblastoid cell lines; and (B) in cell lines derived from patients with rapid (length <2 years, Fast) compared to slowly (length >4 years,
Slow) progressive C9ORF72-ALS.
doi:10.1371/journal.pone.0127376.g004
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Dysregulation of gene networks related to glucose and cholesterol metabolism, both of
which were down-regulated in C9ORF72-ALS motor neurons, is interesting. Increasingly ER
stress is implicated in ALS. As well as a site of lipid synthesis, the ER is responsible for correct
protein folding [18]. Protein aggregates are a prominent feature of all forms of ALS; ER stress
activates the unfolded protein response (UPR) and chronically can lead to apoptosis. Indeed
activation of the UPR has been observed in sporadic ALS patients [19]. ER stress has been ob-
served to impact negatively on cholesterol synthesis [20]. In a different cell model we have pre-
viously demonstrated a deficit in glucose metabolism associated with ALS [21].
Transcriptome analysis in C9ORF72-ALS lymphoblastoid cells
Nine transcript networks were identified as differentially expressed between C9ORF72-ALS
and control lymphoblastoid cells (Fig 2, Table 2). With the exception of the gene network en-
riched for ‘RNA splicing’, the functional enrichment of differentially expressed networks in the
C9ORF72-ALS lymphoblastoid cells and motor neurons was distinct. This is not unexpected
given the use of non-overlapping cases in the sample sets and different analysis platforms;
Fig 5. RNA foci in lymphoblastoid cell lines derived from patients with short or long survival.RNA FISH was performed for sense and antisense RNA
foci in lymphoblastoid cells. Example cells are shown derived from patients with rapid (length <2 years, Fast, upper panels) compared to slowly (length >4
years, Slow, lower panels) progressive C9ORF72-ALS. GGGGCC-repeat sense RNA foci are visualised (arrowheads) in the left panels whereas GGCCCC-
repeat antisense RNA foci are visualised (arrowheads) in the right panels. Scale bar 10 µm.
doi:10.1371/journal.pone.0127376.g005
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indeed this makes the identification of a common network all the more robust. Moreover,
there are differences in physiology between the cell types: motor neurons are post-mitotic
whereas lymphoblastoid cells are actively dividing which may explain why ‘regulation of nucle-
ar division’ did not appear in the lymphoblastoid cell networks.
Some common themes arise in the enrichment of the differentially expressed networks in
the lymphoblastoid cells: three networks were enriched for functional categories related to
nerve or muscle function (Table 2). This suggests that the presence of the expansion in the
lymphoblastoid cells has an effect on genes important for neuromuscular function. Even if not
deleterious to the lymphoblastoid cells, these same changes may be toxic if they occur in the
cell types vulnerable to the neurodegenerative pathology in ALS. Two networks were enriched
for functional categories related to protein catabolism (Table 2). Failure of protein catabolism
has been implicated previously in ALS [22], indeed several genetic variants of ALS are caused
by mutations in genes with roles in protein degradation e.g. VCP [23] and UBQLN2 [24]. Two
networks were enriched for functional categories related to regulation of apoptosis (Table 2).
Dysregulation of pathways related to apoptosis has also been previously implicated in ALS
[25]. Both protein processing and regulation of apoptosis have been linked to ALS in the con-
text of ER stress [18]; misfolded protein accumulation can induce ER stress, and chronic ER
stress can lead to apoptosis.
A network of genes enriched for ‘RNA splicing’ as was up-regulated in both cell types under
examination suggesting that it may represent an upstream effect of the expansion. Analysis of
the ‘RNA splicing’ network signal in both models showed that the similarity extended beyond
the functional enrichment to the actual genes dysregulated. Moreover the dysregulated gene
lists were significantly enriched with independently generated candidate protein binding part-
ners of the GGGGCC-repeat expansion from our own work [8] and that of others [7,26,27].
We have previously proposed that C9ORF72-disease involves dynamic sequestration of a sig-
nificant number of RBPs involved in mRNA splicing, by RNA foci transcribed from the
GGGGCC repeat [8]. The observed up-regulation of genes encoding these proteins in both
C9ORF72-ALS motor neurons and lymphoblastoid cells is consistent with attempted compen-
sation by the cell for a sequestration process.
Exon splicing in C9ORF72-ALS lymphoblastoid cells
In view of these findings we attempted to examine global splicing function within the cell. De-
spite their being non-neuronal, we utilised lymphoblastoid cells in this analysis because of the
large number of samples available and the accessibility of high quality RNA. It is reasonable to
expect that a molecular phenotype observed in lymphoblastoid cells might also be present in
the central nervous system (CNS). We have previously shown that detectable C9ORF72 expan-
sion length [28] and transcription of RNA foci [8] are comparable between lymphoblastoid cell
lines and the CNS.
Splicing errors are likely to be a normal occurrence for which the cell is able to compensate
[13]. However, if the load of these errors is increased then the compensatory mechanism may
be overcome and the probability of this occurring might be expected to increase with time.
This is consistent with the late age of onset and markedly variable phenotype found in
C9ORF72-disease. In order to quantify splicing errors, we defined functionally appropriate
splicing as likely to be consistent between members of a particular group: C9ORF72-ALS, non-
C9ORF72 ALS or controls. We identified a reduction in splicing consistency, or an increase in
the splicing error rate, in C9ORF72-ALS samples compared to non-C9ORF72 ALS samples and
controls; moreover the splicing error rate was higher in samples derived from C9ORF72-ALS
patients with shorter survival compared to samples derived from C9ORF72-ALS patients with
Splicing Dysregulation in C9ORF72-ALS
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a longer survival, suggesting a link with CNS toxicity. Consistent with our hypothesis there was
a trend for the frequency of sense RNA foci to be higher in lymphoblastoid cell lines derived
from patients with a shorter survival; this might be expected to increase the sequestration of
RNA splicing proteins and thus exacerbate the production of splicing errors.
A number of studies have previously examined the transcriptome in the presence of expand-
ed C9ORF72 [3–5,29]; the findings of these studies have so far been inconsistent. An increase
in the number of splicing errors is a potential explanation for this finding. We await further
validation of our results using new technologies such as RNA sequencing and utilising newly
emerging disease models including iPS derived motor neurons from patients with C9ORF72
mutations.
Materials and Methods
Transcriptome analysis
Laser captured motor neurones. Brain and spinal cord tissue from eight C9ORF72-ALS
patients and three neurologically normal human control subjects was obtained from the Shef-
field Brain Tissue Bank (Table 3). C9ORF72-ALS samples were identified by repeat-primed
PCR of the C9ORF72 gene [1,2]. Clinically these patients resembled the full clinical spectrum
of C9ORF72-ALS: Mean age of onset was 61 years (range 56 to 66 years) and mean disease du-
ration was approximately 2 years (range 7 months to 43 months). Tissue donated for research
was obtained with written informed consent from the next of kin, and in accordance with the
UK Human Tissue Authority guidelines on tissue donation. The work was approved by the
South Yorkshire Ethics Committee.
Spinal cord sections from the limb enlargements were collected postmortem, processed ac-
cording to standard protocols [30], and stored at −80ºC until required. Cervical spinal cord sec-
tions were prepared, between 800 and 1200 motor neurons were isolated and RNA was
extracted using methods described previously [31]. RNA quantity and quality was assessed on
the Nanodrop spectrophotometer and Agilent Bioanalyser, respectively, to ensure all samples
were of comparable and sufficient quality to proceed. RNA (20–25ng) was linearly amplified
using the Affymetrix Two Cycle cDNA synthesis protocol to produce biotin-labelled copy
RNA. Copy RNA (15μg) was fragmented for 15min and hybridized to the Human Genome
U133 Plus 2.0 GeneChips, according to Affymetrix protocols. Array washing and staining was
Table 3. Clinical information relating to motor neurons laser captured from ALS patients and controls, utilised in gene level microarray analysis.
Sample Type Gender Age Duration Diagnosis Presentation C9orf72
Control1 F 52 - - - -
Control2 M 63 - - - -
Control3 F 65 - - - -
Patient1 F 62 2.00 Familial Bulbar +
Patient2 F 61 3.33 Sporadic Bulbar +
Patient3 M 66 1.17 Familial Bulbar +
Patient4 F 56 3.58 Familial Limb +
Patient5 M 62 1.67 Sporadic Bulbar +
Patient6 F 61 3.50 Sporadic Limb +
Patient7 M 70 2.17 Familial Limb +
Patient8 F 58 0.58 Sporadic Limb +
Age at symptom onset and disease duration is provided in years. Abbreviations: M = male, F = female.
doi:10.1371/journal.pone.0127376.t003
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performed in the GeneChip fluidics station 400 and arrays were scanned on the GeneChip
3000 scanner. GeneChip Operating Software (GCOS) was used to generate signal intensities
for each transcript.
Data Analysis. Data were normalised using the Puma package which quantifies technical
variability to improve the estimation of gene expression [32, 33]. The next step was to identify
networks of genes with correlated expression which are likely to represent functional groups.
To reduce the computational burden and enhance the signal strength in the data, genes were
ranked by t-statistic in a disease versus control comparison; the top 10,000 genes were then
taken forward. For network detection, genes were further filtered to find the 5000 most con-
nected (as quantified by Pearson correlation coefficient) genes; by definition, networked genes
are strongly connected and therefore this should not lead to loss of information [34]. Network
detection was performed using the weighted gene coexpression network analysis (WGCNA)
package [35]. The correlation between expression of a given network of genes and whether a
sample was a C9ORF72-case or a control was quantified and a Student’s asymptotic p-value
calculated; p-values<0.05 were taken to be significant. Differentially expressed networks were
examined and an enrichment analysis performed using the Database for Annotation, Visuali-
zation and Integrated Discovery (DAVID) [36,37]. Enrichment was calculated by functional
annotation clustering using the ‘high’ i.e. specific, Gene Ontology ‘biological processes’ terms.
Lymphoblastoid cell lines. Lymphoblastoid cell lines derived from Caucasian ALS pa-
tients (n = 56) and neurologically normal controls (n = 15), all of Northern European descent,
were obtained from the UKMotor Neurone Disease Association (MNDA) DNA Bank
(Table 4). C9ORF72-ALS samples were identified by repeat-primed PCR of the C9ORF72 gene
[1,2]. Clinically these patients resembled the full clinical spectrum of C9ORF72-ALS: Mean age
of onset was 58 years (range 28 to 75 years) and mean disease duration was approximately
2 years (range 2 months to 83 months). All samples were collected with written informed con-
sent from the donor, and the work was approved by the South Yorkshire Ethics Committee.
Total RNA was extracted from ALS patient and control-derived lymphoblastoid cell lines
using QIAGEN’s RNeasy Mini Kit following the manufacturer’s recommendations. A 75µL
LCL suspension, containing approximately 5x106 cells, typically yields between 1.9 and 13.6µg
total RNA with a mean concentration of approximately 170ng/µl as assessed the by the Nano-
Drop 1000 spectrophotometer (Thermo Scientific). The quality of the isolated material was
analysed using the 2100 bioanalyzer with an RNA 6000 Nano LabChip Kit (Agilent Technolo-
gies, Inc.). Linear amplification of RNA with an input of approximately 300ng of starting mate-
rial was performed using the AmbionWhole Transcript (WT) Expression Assay (Applied
Biosystems) and Affymetrix GeneChip WT Terminal Labelling Kit. This procedure generated
fragments of biotin-labelled sense-stranded copy DNA (6–10µg) between 40 and 70 nucleo-
tides in length that were hybridized onto Human Exon 1.0ST GeneChip Arrays according to
Affymetrix protocols. Array washing, staining and visualisation were performed as described
for motor neuron derived RNA.
Data analysis. Network analysis of gene expression in the lymphoblastoid cell lines was
identical to that in the motor neurons. However, because of the exon level probing, after Puma
normalisation, approximately twice as many transcripts were quantified. This was taken into
consideration in the filtering steps and the same proportion of transcripts were analysed at
each stage rather than the exact same number i.e. the top 20,000 genes ranked by t-statistic
were filtered to the 10,000 most connected for the network analysis.
Exon level data were analysed using the ‘finding isoforms using robust multichip analysis’
(FIRMA) package [38] which itself is part of the Aroma Affymetrix package [39]. The FIRMA
step was then applied to detect alternative splicing; a FIRMA score is calculated for each exon.
The score represents the result of fitting a transcript-level model to the observed data and
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Table 4. Clinical information relating to lymphoblastoid cell lines derived from ALS patients and controls, utilised in exon level microarray
analysis.
Sample Type Gender Age Duration Diagnosis Presentation C9orf72
Control1 F 52 - - - -
Control2 M 69 - - - -
Control3 F 65 - - - -
Control4 F 84 - - - -
Control5 M 56 - - - -
Control6 F 59 - - - -
Control7 M 73 - - - -
Control8 F 67 - - - -
Control9 M 47 - - - -
Control10 M 64 - - - -
Control11 F 41 - - - -
Control12 M 36 - - - -
Control13 M 61 - - - -
Control14 M 54 - - - -
Control15 F 63 - - - -
Patient1 F 69 >4.00 Familial Limb +
Patient2 F 61 2.96 Familial Limb -
Patient3 F 28 1.10 Familial Bulbar +
Patient4 M 44 2.11 Familial Respiratory -
Patient5 F 46 Unknown Familial Bulbar -
Patient6 M 69 1.76 Familial Limb +
Patient7 M 48 Unknown Familial Mixed -
Patient8 M 57 5.71 Familial Mixed -
Patient9 F 57 1.21 Familial Mixed +
Patient10 M 63 >5.00 Familial Limb +
Patient11 F 62 0.17 Familial Bulbar +
Patient12 F 64 6.92 Familial Limb +
Patient13 M 59 <1.00 Familial Unknown +
Patient14 M 63 1.71 Familial Mixed +
Patient15 F 56 4.14 Familial Limb +
Patient16 M 47 1.63 Familial Limb +
Patient17 F 51 0.97 Familial Bulbar +
Patient18 F 61 Unknown Familial Bulbar -
Patient19 M 73 1.88 Sporadic Respiratory -
Patient20 M 60 1.15 Sporadic Bulbar +
Patient21 M 64 2.36 Sporadic Bulbar -
Patient22 F 68 3.31 Sporadic Bulbar -
Patient23 M 68 1.56 Sporadic Limb +
Patient24 F 72 4.66 Sporadic Limb +
Patient25 M 58 1.40 Sporadic Bulbar -
Patient26 M 54 2.89 Sporadic Bulbar -
Patient27 M 53 3.28 Sporadic Limb -
Patient28 F 52 2.25 Sporadic Limb +
Patient29 M 72 2.58 Sporadic Limb -
Patient30 M 60 1.08 Sporadic Bulbar -
Patient31 F 67 1.47 Sporadic Bulbar +
(Continued)
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observing the disparity between the model and the exon-level intensity of each individual exon.
Thus exons with a different level of expression to their parent transcript i.e. those which are
spliced in or out, are identified. Utilising all probes specific for an entire transcript results in a
significant improvement on the estimation of exon expression compared to using the relatively
small number of probes specific to a given exon in isolation. FIRMA scores were log trans-
formed prior to analysis. Highly negative or positive values of the FIRMA score are indicative
of alternative exon skipping or inclusion respectively. The 1st and 99th percentiles of the
FIRMA score for all exons in all samples were used to identify exons with the most evidence of
alternative splicing, as used previously [40].
Consistency of splicing within a sample group such as patients or controls was evaluated by
comparing the number of splicing events which occurred in 1, 2, 3. . .n samples within the
group. To allow comparison between groups, comparison was made with the situation in
which exons are spliced in or out at random. In each case the random situation was modelled
with a Poisson distribution and the observed data were fitted to a negative binomial distribu-
tion (S1 Fig). θ is a quantification of the overdispersion in the negative binomial distribution
with respect to an equivalent Poisson distribution, which is therefore a measure of non-random
choice, i.e. consistency, in the splicing observed in each sample group. The variance of a nega-
tive binomial distribution is given by μ+μ2/θ where μ = mean. In contrast the variance of a
Poisson distribution is equal to μ. Therefore a higher level of θ corresponds to a variance closer
to the Poisson distribution and reduced consistency of splicing.
Table 4. (Continued)
Sample Type Gender Age Duration Diagnosis Presentation C9orf72
Patient32 F 37 1.74 Sporadic Limb +
Patient33 M 56 2.20 Sporadic Limb +
Patient34 M 59 1.84 Sporadic Limb -
Patient35 F 70 2.13 Sporadic Limb -
Patient36 M 38 2.83 Sporadic Mixed -
Patient37 M 45 1.47 Sporadic Limb +
Patient38 F 48 ~4.00 Sporadic Bulbar +
Patient39 F 72 1.87 Sporadic Bulbar -
Patient40 M 72 0.52 Sporadic Limb +
Patient41 F 75 1.05 Sporadic Limb -
Patient42 F 52 2.18 Sporadic Limb -
Patient43 F 58 1.33 Sporadic Mixed +
Patient44 M 47 1.57 Sporadic Limb +
Patient45 F 48 5.95 Sporadic Limb +
Patient46 M 64 0.66 Sporadic Limb +
Patient47 F 37 4.50 Sporadic Bulbar +
Patient48 M 70 1.24 Sporadic Limb -
Patient49 F 70 3.04 Sporadic Limb -
Patient50 M 61 2.57 Sporadic Bulbar -
Patient51 M 62 1.96 Sporadic Limb +
Patient52 F 58 <1.00 Sporadic Bulbar +
Patient53 M 61 ~4.00 Sporadic Mixed +
Patient54 M 65 1.40 Sporadic Limb +
Age at symptom onset and disease duration is provided in years. Abbreviations: M = male, F = female.
doi:10.1371/journal.pone.0127376.t004
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qPCR based validation of transcriptome changes
Total RNA from lymphoblastoid cells was amplified using High Capacity RNA-to-cDNA kit
(Applied Biosystems). Quantitative PCR (QPCR) primers for HNRNPF, FUS, HNRNPH2 and
RBM3 transcripts were designed using Eurofins online primer design software (http://www.
eurofinsdna.com). QPCR of 75 C9ORF72-ALS cases and 35 controls was performed using Bril-
liant II SYBR Green QPCRMaster Mix (Stratagene) on the Stratagene 3000, as described previ-
ously [41]. RNA from groups of five C9ORF72-ALS or five control samples was pooled. These
samples were obtained from the UKMNDA DNA Bank and included those samples utilised in
the microarray analysis, as well as additional samples. T-tests were used to determine if the rel-
ative differences in transcript expression in lymphoblastoid cells between C9ORF72-ALS sam-
ples and controls were statistically significant.
Estimation of expansion size in lymphoblastoid cell lines
GGGGCC expansion size was estimated using a Southern hybridisation based protocol as pre-
viously described [28] using DNA derived from patients with rapid (<2 years, n = 17) or slowly
(>4 years, n = 7) progressive disease.
Quantification of abundance of RNA foci in lymphoblastoid cell lines
A 5’ TYE-563-labeled LNA (16-mer fluorescent)-incorporated DNA probe was used against
the sense (Exiqon, Inc.; batch number 607323) and the antisense RNA hexanucleotide repeat
(Exiqon, Inc.; batch number 610331). Slides were prepared and RNA foci were visualised as de-
scribed previously [8]. More than fifty lymphoblastoid cells derived from patients with rapid
(<2 years, n = 3) or slowly (>4 years, n = 3) progressive disease were imaged.
Supporting Information
S1 Fig. Quantification of splicing events shared between lymphoblastoid cell lines of each
sample group. Plots of the number of splicing events (y-axis) which were present in a given
number of lymphoblastoid cell lines (x-axis) within a particular sample group. Sample groups
from top to bottom are: normal controls, C9ORF72-ALS patients, non-C9ORF72 ALS patients,
C9ORF72-ALS patients with survival<2 years and C9ORF72-ALS patients with survival>4
years. In each plot the left-hand line represents a Poisson fit to the observed data i.e. the ran-
dom case. The right-hand line is the observed data and the dotted line represents the negative
binomial distribution fit to the observed data. In each case the negative binomial provides a rel-
atively good fit to the observed data. θ as shown in Fig 4, is a quantification of the overdisper-
sion in the negative binomial compared to the Poisson fit to the observed data i.e. the degree of
consistency in the splicing observed in each sample group.
(TIF)
S1 Table. Genes associated with the ‘RNA splicing' network signal and within the GO term
‘RNA Processing.’ Genes listed are within the GO category ‘RNA Processing’ and are signifi-
cantly associated (p<0.05) with the ‘RNA splicing' network signal in either C9ORF72+ lympho-
blastoid cell lines or motor neurons. A fold change of>1 equates to up-regulation and a fold
change of<1 equates to down-regulation.
(XLSX)
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Transcript ID
Fold Change 
(C9ORF72+ Vs 
Control)
Transcript ID
Fold Change 
(C9ORF72+ Vs 
Control)
A1CF ENST00000373995 1.24
A2BP1 ENST00000340209 0.41
ENST00000441315 1.19 1555371_at 0.43
ENST00000406935 1.22
ENST00000268624 0.93
ENST00000315906 2.78
ADAR ENST00000492630 1.34
ADARB1 ENST00000481022 0.74
ENST00000342031 1.73
ENST00000367594 1.16
ADAT3 ENST00000454697 1.84
ENST00000348990 5.45
ENST00000359726 5.54
ENST00000466453 0.38
ENST00000464867 0.73
ENST00000491395 0.69
ARL6IP4 ENST00000315580 1.18
ENST00000483591 1.12
ENST00000483954 1.43
ENST00000462421 0.81
ENST00000458215 0.67
ENST00000407324 1.07
ENST00000470189 0.86
ENST00000407324 1.07
ENST00000470189 0.86
ENST00000407324 1.07
ENST00000470189 0.86
C1ORF66 ENST00000462397 0.81
CCAR1 ENST00000480627 2.43
ENST00000473791 0.82
ENST00000375351 1.99
ENST00000304494 1.12
ENST00000470819 1.09
ENST00000380150 0.88
CELF1 ENST00000395292 1.16
CELF6 ENST00000287202 0.86
CPSF3 ENST00000489403 1.22
ENST00000458452 1.45
ENST00000430786 0.4
ENST00000421495 5.21
ENST00000435064 4.64
S1 Table
APP
ATXN1
BAT1
C1D
C1DP2
C1DP3
Gene Symbol
Lymphoblastoid Cell Lines Motor Neurons
ABCB5
ADAD2
ADAT2
CDK5RAP1
CDKN2A
CPSF3L
ENST00000496353 0.85
ENST00000450926 4.03
ENST00000467408 0.62
ENST00000419704 4.08
ENST00000478641 0.79
ENST00000294579 4.4
ENST00000465132 1.31
ENST00000412686 1.1
CPSF7 ENST00000413232 2.14 217866_at 1.53
CRNKL1 ENST00000490258 0.82
CSDC2 ENST00000460790 1.22
CSTF1 ENST00000428552 2.01
CSTF2 ENST00000415585 0.8
DDX1 ENST00000478695 1.95
ENST00000479734 1.15 208718_at 1.32
ENST00000475004 1.77
ENST00000477112 1.13
ENST00000448192 1.13
ENST00000473924 2.05
DHX16 ENST00000480966 1.09
DHX35 ENST00000449559 1.77
DHX9 ENST00000483416 1.17
DIS3 ENST00000475871 1.17
ENST00000492372 2.03
ENST00000475423 1.22
ENST00000413910 2.08
DUS3L ENST00000428664 2.01
ENST00000426905 9.67
ENST00000476042 0.48
ENST00000484122 1.15
ENST00000407336 0.35
ENST00000427703 4.86
ENST00000395962 9.49
ENST00000491478 0.75
ENST00000338034 20.7
ELAVL4 ENST00000474675 1.2
EXOSC1 ENST00000489158 1.15
EXOSC10 ENST00000469634 0.89
EXOSC3 ENST00000482614 0.83
ENST00000459856 1.79
ENST00000461361 0.88
ENST00000389704 1.18
ENST00000488779 2.55
ENST00000488108 0.63
ENST00000379809 2.71
ENST00000495092 4.32
FARS2 ENST00000274680 0.81
ENST00000485486 2.26
ENST00000466371 1.86
DKC1
ELAC2
EXOSC7
EXOSC8
FTSJ1
CPSF4
DDX17
DDX56
CPSF3L
ENST00000487353 0.89
FTSJ2 ENST00000486040 1.1
ENST00000491029 2.76 215744_at 0.39
ENST00000483853 1.18
ENST00000474990 1.31
GEMIN6 ENST00000281950 1.23
GTF2F2 ENST00000461904 1.15
ENST00000495810 1.21
ENST00000490912 1.13
HNRNPA3 ENST00000432457 1.99
ENST00000336053 2.5
ENST00000320084 2.5
HNRNPF ENST00000437529 3.39
HNRNPH2 ENST00000457902 2.19 201406_at 1.88
ENST00000467249 1.92 208990_s_at 2.16
ENST00000480987 2.73
ENST00000469172 1.17
HNRNPK ENST00000481820 1.24
HNRNPL ENST00000423415 1.19
HNRNPM ENST00000348943 3.89 233605_x_at 0.73
ENST00000476660 0.84
ENST00000464516 1.46
ENST00000478691 1.15
ENST00000283179 4.3
ENST00000465881 1.22
ENST00000413625 0.66
ENST00000483966 1.32
ENST00000270069 1.13
ENST00000392006 1.21
ENST00000263367 1.21
HNRPLL ENST00000410076 1.14
HSD17B10 ENST00000495986 1.2
HSD3B7 ENST00000454009 0.93
IMP4 ENST00000462392 2.96
INTS12 ENST00000493425 1.26
INTS4 ENST00000433818 1.12
INTS6 ENST00000440606 1.11
ENST00000468217 1.18
ENST00000392007 0.5
ENST00000494880 1.23
KRR1 ENST00000229214 1.14 203203_s_at 2.13
LARP6 ENST00000344870 1.1
LARP7 ENST00000344442 1.2
LOC100130109 ENST00000469451 1.79
ENST00000492779 0.74 227223_at 2.44
ENST00000427743 1.93
LOC644063 ENST00000481820 1.24
LOC644390 ENST00000423415 1.19
LOC644422 ENST00000328748 1.31
IVNS1ABP
LOC643167
HNRNPA2B1
HNRNPC
HNRNPH3
HNRNPR
HNRNPU
HNRNPUL1
FTSJ1
FUS
ENST00000429650 0.72
ENST00000480835 4.3
ENST00000490653 0.61 202126_at 1.87
ENST00000489943 0.31 237093_at 0.4
LOC653884 ENST00000341154 1.22
ENST00000495868 1.25
ENST00000371470 1.16
ENST00000493459 2.16 1558111_at 0.5
ENST00000477171 1.43 1556658_a_at 0.41
ENST00000478535 0.32
ENST00000460166 0.3
ENST00000476172 0.75
ENST00000435176 3.79
ENST00000432299 3.05
ENST00000471160 2.69
ENST00000486416 1.13
ENST00000468427 0.5
ENST00000493360 1.16
ENST00000476969 1.37
ENST00000244230 1.1
ENST00000462039 0.73 224430_s_at 2.26
ENST00000445187 1.22
ENST00000487960 2.92
MTPAP ENST00000488290 1.08
NCBP1 ENST00000375147 1.15
ENST00000447325 2.3
ENST00000482976 3.18
NHP2L1 ENST00000488571 1.14
NOLC1 ENST00000476468 2.07
ENST00000472185 0.17
ENST00000490044 1.27
ENST00000450092 1.23
ENST00000373856 2.4
NOP14 ENST00000398071 1.29
ENST00000462630 1.14
ENST00000470143 1.12
NOP58 ENST00000478508 1.31
NPM3 ENST00000468544 1.91
PA2G4 ENST00000303305 1.12
PA2G4P4 ENST00000303305 1.12
ENST00000492468 2.63
ENST00000372862 3.25
ENST00000451091 0.5
ENST00000492519 0.81
ENST00000470443 0.56
ENST00000461578 0.3
PABPN1 ENST00000397276 1.58
ENST00000359282 1.43
ENST00000359462 1.43
NOP56
PABPC4
PCBP2
MLH1
MOV10
MPHOSPH10
MTO1
NCBP2
NONO
LOC652147
LOC653155
MAGOH
MBNL1
ENST00000439930 1.43
ENST00000490787 1.91
ENST00000466959 0.89
PDCD7 ENST00000380204 2.28
PES1 ENST00000433575 2.42
PIWIL2 ENST00000454009 0.93
ENST00000438333 3.73
ENST00000484821 1.68
POLR2D ENST00000487079 1.37 203664_s_at 0.75
ENST00000476003 1.11
ENST00000490958 1.13
ENST00000460083 1.34
ENST00000486482 0.85
ENST00000430370 1.32
ENST00000446223 1.32
ENST00000427454 1.39
ENST00000467741 0.42
ENST00000482751 1.19
PPIG ENST00000418888 1.16
PPIL1 ENST00000483552 1.27
ENST00000486634 0.65
ENST00000236412 1.19
ENST00000473455 2.09
ENST00000454220 1.32
ENST00000473820 1.47
ENST00000482242 1.98 226317_at 1.5
ENST00000460360 1.19
ENST00000490501 0.77
ENST00000463882 1.13
PRMT5 ENST00000421938 1.31
ENST00000298451 1.75
ENST00000417658 1.24
ENST00000476970 0.68
ENST00000470824 0.86
ENST00000321030 1.19
ENST00000467851 1.75
PRPF38B ENST00000467302 1.26
PRPF4 ENST00000488937 1.17
ENST00000359961 11.19 218053_at 1.26
ENST00000450135 5.78
ENST00000493468 0.38
ENST00000486100 0.4
ENST00000440252 23.92
ENST00000490653 0.61 202126_at 1.87
ENST00000489943 0.31 237093_at 0.4
PTBP2 ENST00000482253 1.22
PUS10 ENST00000421319 1.21
PUS7 ENST00000487277 1.2
ENST00000488665 1.6
PRPF18
PRPF3
PRPF31
PRPF40A
PRPF4B
QTRTD1
PPAN
PPIE
PPP1R8
PPP2R1A
PPP4R2
PRKRA
PCBP2
PDCD11
POLR2B
POLR2H
ENST00000466870 0.79
ENST00000413297 1.22
ENST00000481580 0.87
ENST00000489384 1.08
ENST00000246194 3.7
RBM14 ENST00000409406 0.86 236157_at 0.59
RBM16 ENST00000479234 1.13
ENST00000465906 2.35 224780_at 1.37
ENST00000418631 1.12
ENST00000467214 0.67
ENST00000418869 0.62
ENST00000481147 0.68
ENST00000446108 1.09
ENST00000223073 1.25
ENST00000415472 0.79
ENST00000490127 2.48
ENST00000472897 1.25
ENST00000492779 0.74 227223_at 2.44
ENST00000427743 1.93
RBM4 ENST00000409406 0.86 236157_at 0.59
ENST00000395174 3.76
ENST00000471995 0.65
ENST00000441812 2.96
ENST00000404526 1.8
ENST00000489437 0.64
ENST00000493652 1.15 201967_at 1.4
ENST00000483350 1.15
RBM8A ENST00000369307 2.61
RBM9 ENST00000473487 0.88
ENST00000492283 0.71 225265_at 1.75
ENST00000494308 0.2 238185_at 2.49
ENST00000474820 5.03
ENST00000490637 0.88
ENST00000464200 0.45
ENST00000477965 8.28
ROD1 ENST00000450374 1.99
RP9 ENST00000492391 1.36
RPL11 ENST00000374550 1.98
ENST00000465280 11.32
ENST00000477056 1.14
ENST00000461368 2.28
ENST00000448864 0.61
ENST00000464167 1.45
ENST00000442341 1.28
ENST00000496582 3.6
RPL36A ENST00000457902 2.19 201406_at 1.88
RPL5 ENST00000497519 1.29
ENST00000396466 6.07
ENST00000396465 1.14
RBM6
RBMS1
RPL14
RPL35A
RPL7
RALY
RBM17
RBM28
RBM3
RBM39
RBM5
QTRTD1
ENST00000431653 1.67
ENST00000462046 0.42
ENST00000477305 2.84
ENST00000461393 3.35
ENST00000481972 2.34
ENST00000474660 2.53
RPP30 ENST00000480635 0.87
ENST00000339471 1.17 213890_x_at 1.79
226131_s_at 1.6
RPS24 ENST00000435275 0.48
ENST00000380381 1.27
ENST00000380384 1.09
ENST00000304921 1.15
ENST00000479123 1.81
RRAGC ENST00000474456 1.24
ENST00000473988 0.64
ENST00000475534 2.48
RSRC1 ENST00000494002 1.13
RTCD1 ENST00000260563 0.83
SBDS ENST00000496763 2.02
ENST00000461862 1.35
ENST00000471039 1.35
SETX ENST00000419901 1.17 232229_at 0.61
ENST00000448404 6.38
ENST00000496969 0.41
ENST00000477596 0.85
ENST00000416674 0.63
ENST00000413951 0.35
ENST00000377387 1.22
ENST00000377394 5.41
ENST00000422298 4.67
ENST00000463343 2.29
ENST00000334944 12.45
ENST00000489544 0.11
ENST00000485618 1.51 201356_at 1.39
ENST00000444440 1.39
ENST00000488934 1.14
ENST00000487062 1.21
ENST00000470585 1.19
ENST00000462613 1.89
ENST00000479532 0.83
ENST00000409915 1.28
SF3B2 ENST00000322535 1.12
SF3B4 ENST00000271628 1.08 209044_x_at 1.54
ENST00000485365 1.73 226898_s_at 0.43
ENST00000485454 1.3 214016_s_at 1.21
ENST00000470472 1.98
ENST00000471991 1.22
ENST00000466745 0.67
SF3A1
SF3A3
SF3B1
SFPQ
RPS16
RPS6
RPS7
RRP1
SCNM1
SF1
RPL7
RPP14
SFRS1 ENST00000423765 1.21 211784_s_at 1.27
ENST00000454435 0.4
ENST00000429640 3.05
ENST00000475204 0.65
ENST00000463116 0.37
ENST00000370950 1.3
ENST00000469170 1.94
ENST00000395136 0.71
SFRS13A ENST00000341154 1.22
ENST00000488604 1.45
ENST00000475068 1.12
ENST00000452027 0.87
SFRS15 ENST00000467731 1.13 222310_at 2.84
ENST00000313871 3.18
ENST00000440218 0.63
ENST00000497015 1.62
ENST00000477193 1.08
SFRS5 ENST00000394366 1.15
SFRS6 ENST00000328748 1.31
ENST00000378869 0.46
ENST00000415527 1.23
SLBP ENST00000489418 1.16
SMC1A ENST00000322213 1.29 201589_at 4.17
SMNDC1 ENST00000471297 1.12
ENST00000429650 0.72
ENST00000480835 4.3
ENST00000441315 1.19 1555371_at 0.43
ENST00000406935 1.22
ENST00000397475 2.58
ENST00000496946 1.13
SNRPB ENST00000381342 2.86 208821_at 4.18
SNRPE ENST00000469451 1.79
SNRPEL1 ENST00000469451 1.79
SNRPN ENST00000346403 1.25
SPOP ENST00000347630 1.1
ENST00000485374 3.31
ENST00000461941 87.15
ENST00000461844 1.7
ENST00000493598 4.14
ENST00000496100 4.65
ENST00000465112 1.27
ENST00000462282 1.14
ENST00000493638 1.21
ENST00000471693 0.9
ENST00000485541 1.29
ENST00000474843 0.75
ENST00000445337 2.15 214127_s_at 0.33
ENST00000487311 1.35
ENST00000466432 0.84
SR140
SRPK2
SRRM1
SRRT
SFRS17A
SFRS4
SFRS7
SNRNP200
SNRNP35
SNRNP48
SFRS11
SFRS13B
ENST00000449389 1.54
ENST00000474896 0.86
ENST00000474273 1.41
ENST00000461708 0.81
ENST00000470621 1.15
SYF2 ENST00000476231 0.85
ENST00000449619 1.41 236146_at 2.42
217834_s_at 1.32
TARBP2 ENST00000266987 1.16 200020_at 1.31
TARDBP ENST00000480464 1.51
ENST00000422283 2.16
ENST00000450493 0.21
ENST00000492137 0.87
ENST00000481357 0.39
ENST00000407431 1.11
ENST00000441692 1.2
ENST00000432353 3.09
ENST00000496830 0.6
ENST00000419633 0.58
ENST00000492203 0.21
ENST00000464604 0.68
TRA2A ENST00000482395 0.91
ENST00000453386 1.19
ENST00000342294 1.62
ENST00000485530 2.63
ENST00000372939 1.31
ENST00000490509 0.49
TRMT6 ENST00000473131 1.09
TRMT61B ENST00000484060 0.54
TRMU ENST00000424260 1.55
TRPT1 ENST00000394547 1.31
ENST00000461180 1.23
ENST00000372890 1.13
ENST00000462677 1.54
ENST00000367518 0.8
ENST00000485209 1.08
TSEN54 ENST00000434205 3.02
TTF2 ENST00000463696 3.79
TYW1 ENST00000491969 16.5
TYW3 ENST00000486467 1.1
U2AF1 ENST00000478282 1.07
UPF3B ENST00000276201 1.59
URM1 ENST00000372847 1.3
ENST00000409470 5.52
ENST00000409025 3.77
ENST00000323701 3.65
ENST00000481409 0.03
ENST00000451004 2.59
ENST00000450066 3.24
USP39
TFIP11
THOC2
TRA2B
TRMT2B
TRUB2
TSEN15
SRRT
SSB
SYNCRIP
ENST00000474572 0.1
ENST00000459775 8.41
ENST00000467885 0.33
UTP11L ENST00000486563 0.74
UTP14A ENST00000498179 1.1 221098_x_at 0.53
UTP6 ENST00000490218 1.3
WDR12 ENST00000478869 2.4
WDR4 ENST00000330317 1.18
WDR77 ENST00000459665 1.16
XRN2 ENST00000430571 1.35 208627_s_at 0.53
ENST00000436427 1.12
ENST00000318612 1.79
ENST00000332220 1.22
YTHDC1 ENST00000344157 1.18
ENST00000466440 0.94
ENST00000470212 2.55
ZCCHC6 ENST00000375947 1.15 244499_at 0.45
ZFC3H1 ENST00000308101 1.29
ZMAT5 ENST00000397781 0.44
ENST00000487638 1.38
ENST00000492262 1.37
ENST00000411930 0.39
ENST00000494621 1.49
ENST00000460310 1.35
ENST00000417778 1.31
ZRANB2 ENST00000370920 1.19 213876_x_at 2.22
ENST00000380308 1.19
ENST00000468028 1.48
BICD1 242052_at 2.67
1565599_at 0.29
214405_at 1.52
CELF3 206817_x_at 0.34
CLP1 204370_at 1.92
226153_s_at 2.23
238438_at 2.15
DDX20 224315_at 1.52
DDX46 229098_s_at 2.03
DEDD2 225434_at 1.28
214280_x_at 1.28
200016_x_at 1.43
INTS2 224308_s_at 1.68
215233_at 2.64
212723_at 1.58
KIAA1429 223110_at 2.2
LOC643446 207939_x_at 2.68
214280_x_at 1.28
200016_x_at 1.43
LSM7 204559_s_at 2.31
LUC7L3 220044_x_at 1.37
CNOT6L
HNRNPA1
JMJD6
LOC644037
USP39
YBX1
ZCCHC11
ZNF638
ZRSR2
CELF2
NOVA1 207437_at 1.98
NSUN2 223076_s_at 1.36
PABPC1 215157_x_at 1.35
PAPOLA 228569_at 1.6
PPARGC1A 219195_at 2.49
PTBP1 211271_x_at 3.97
RBM15B 226987_at 2.3
RBM22 236872_at 0.47
RBM25 212030_at 1.82
RBMS2 235558_at 0.37
RNPS1 207939_x_at 2.68
211487_x_at 1.92
212578_x_at 1.76
201665_x_at 2.61
RPS19 202649_x_at 1.66
RRP1B 212844_at 0.47
SFRS3 202899_s_at 2.35
SMAD1 208015_at 0.34
TGS1 236371_s_at 0.41
THOC1 204064_at 2.71
RPS17
